Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells.
Oncotarget
; 5(20): 9992-10001, 2014 Oct 30.
Article
en En
| MEDLINE
| ID: mdl-25393982
ABSTRACT
Cancer cells survive escaping normal apoptosis and the blocks in apoptosis that keep cancer cells alive are promising candidates for targeted therapy. Galectin-3 (Gal-3) is, a member of the lectin family, which is involved in cell growth, adhesion, proliferation and apoptosis. It remains elusive to understand the role of Gal-3 on apoptosis in thyroid carcinoma cells. Here, we report that Gal-3 heterodimerizes Bax, mediated by the carbohydrate recognition domain (CRD) of Gal-3, leading to anti-apoptotic characteristic. Gal-3/Bax interaction was suppressed by an antagonist of Gal-3, in which in turn cells became sensitive to apoptosis. The data presented here highlight that Gal-3 is involved in the anti-apoptosis of thyroid carcinoma cells. Thus, it suggests that targeting Gal-3 may lead to an improved therapeutic modality for thyroid cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Tiroides
/
Galectina 3
/
Proteína X Asociada a bcl-2
Límite:
Humans
Idioma:
En
Revista:
Oncotarget
Año:
2014
Tipo del documento:
Article